Jo Robson Jo.Robson@uwe.ac.uk
Consultant Associate Professor in Rheumatology
Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials
Robson, Joanna; Doll, Helen; Suppiah, Ravi; Flossmann, Oliver; Harper, Lorraine; H�glund, Peter; Jayne, David; Mahr, Alfred; Westman, Kerstin; Luqmani, Raashid
Authors
Helen Doll
Ravi Suppiah
Oliver Flossmann
Lorraine Harper
Peter H�glund
David Jayne
Alfred Mahr
Kerstin Westman
Raashid Luqmani
Abstract
Objectives To describe short-term (up to 12 months) and long-term (up to 7 years) damage in patients with newly diagnosed antineutrophil-cytoplasm antibody-associated vasculitis (AAV).
Methods Data were combined from six European Vasculitis Study group trials (n=735). Long-term follow-up (LTFU) data available for patients from four trials (n=535). Damage accrued was quantified by the Vasculitis Damage Index (VDI). Sixteen damage items were defined a priori as being potentially treatment-related.
Results VDI data were available for 629 of 735 patients (85.6%) at baseline, at which time 217/629 (34.5%) had ≥1 item of damage and 32 (5.1%) ≥5 items, reflecting disease manifestations prior to diagnosis and trial enrolment. LTFU data were available for 467/535 (87.3%) at a mean of 7.3 years postdiagnosis. 302/535 patients (56.4%) had VDI data at LTFU, with 104/302 (34.4%) having ≥5 items and only 24 (7.9%) no items of damage. At 6 months and LTFU, the most frequent items were proteinuria, impaired glomerular filtration rate, hypertension, nasal crusting, hearing loss and peripheral neuropathy. The frequency of damage, including potentially treatment-related damage, rose over time (p < 0.01). At LTFU, the most commonly reported items of treatment-related damage were hypertension (41.5%; 95% CI 35.6 to 47.4%), osteoporosis (14.1%; 9.9 to 18.2%), malignancy (12.6%; 8.6 to 16.6%), and diabetes (10.4%; 6.7 to 14.0%).
Conclusions In AAV, renal, otolaryngological and treatment-related (cardiovascular, disease, diabetes, osteoporosis and malignancy) damage increases over time, with around one-third of patients having ≥5 items of damage at a mean of 7 years postdiagnosis.
Journal Article Type | Article |
---|---|
Acceptance Date | Oct 29, 2013 |
Online Publication Date | Nov 15, 2013 |
Publication Date | Jan 1, 2015 |
Deposit Date | Jul 2, 2019 |
Journal | Annals of the Rheumatic Diseases |
Print ISSN | 0003-4967 |
Electronic ISSN | 1468-2060 |
Publisher | BMJ Publishing Group |
Peer Reviewed | Peer Reviewed |
Volume | 74 |
Issue | 1 |
Pages | 177-184 |
DOI | https://doi.org/10.1136/annrheumdis-2013-203927 |
Public URL | https://uwe-repository.worktribe.com/output/1467261 |
Publisher URL | https://doi.org/10.1136/annrheumdis-2013-203927 |
You might also like
The OMERACT emerging leaders program: The good, the bad, and the future
(2019)
Journal Article
Update on outcome measure development in large-vessel vasculitis: Report from OMERACT 2018
(2019)
Journal Article
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search